Infant Formula Made in America Act of 2025
HB2008, titled the Infant Formula Made in America Act of 2025, would amend the Internal Revenue Code to create two new federal tax incentives for domestic infant formula manufacturing. First, it establishes a 30 percent investment credit for qualified investments in projects that re-equip, expand, or build U.S. facilities that manufacture eligible infant formula. Second, it creates a production credit of $2 per pound of eligible infant formula manufactured and sold for use in the United States, subject to limits and a five-year eligibility window for each taxpayer.
The bill includes detailed eligibility and administration rules. Both credits are limited to taxpayers with no more than $750 million in global revenue, and the investment credit is capped at $150 million per project and $750 million in total allocations. The Secretary of the Treasury would have to create a certification program within 180 days, review allocations after four years, and may reallocate unused credits. The bill also makes the credits transferable and eligible for elective payment, and it applies recapture rules if a project fails to meet certification requirements or the property ceases to qualify.
In terms of state and federal law impact, the bill would amend multiple sections of the Internal Revenue Code, including sections 38, 46, 49, 6417, and 6418, and add new sections 48F and 45BB. It would not directly change state law, but it would alter federal tax treatment for infant formula manufacturers and could influence where companies invest in production capacity. The credits would apply only to projects beginning construction after enactment and to formula manufactured after enactment, respectively.
The available context shows little recorded debate or voting activity, and the bill was simply referred to the House Committee on Ways and Means. As a result, there is no documented committee sentiment in the provided materials. Based on the bill text alone, the measure appears designed to support domestic manufacturing and supply-chain resilience for infant formula, with a policy emphasis on increasing U.S.-based production and reducing reliance on foreign supply.
Notable points of potential contention include the use of federal tax credits to subsidize private manufacturing, the size of the aggregate credit cap, and the restriction to companies below the $750 million global revenue threshold. The bill also conditions benefits on domestic sales and U.S. manufacturing, which may raise questions about market effects, administrative complexity, and whether the incentives are targeted narrowly enough to avoid subsidizing larger firms or projects with limited public benefit.
HB2008 would add new federal tax credits to the Internal Revenue Code for domestic infant formula manufacturing, including a 30 percent investment credit for qualifying facility projects and a per-pound production credit for eligible formula sold in the United States. It would amend sections 38, 46, 49, 6417, and 6418, and create new sections 48F and 45BB. The bill would not directly amend state statutes, but it would affect manufacturers, investors, and tax administration at the federal level by making these credits transferable and eligible for elective payment, while imposing certification, recapture, and allocation limits.
The provided record contains no committee transcript, vote tally, or recorded floor debate, so there is no direct evidence of partisan or stakeholder sentiment from the legislative history. From the bill text and title, the measure appears broadly pro-manufacturing and pro-supply-chain security, aimed at encouraging domestic infant formula production. The absence of recorded opposition or support in the supplied context means sentiment cannot be assessed beyond the bill’s apparent policy intent.
The main likely points of contention are the cost and scope of the tax incentives, the $750 million aggregate cap, and the revenue threshold limiting eligibility to smaller taxpayers. Critics could question whether federal tax credits are the best tool to address infant formula supply issues, while supporters may argue the credits are necessary to expand domestic capacity and reduce dependence on imports. The certification process, domestic-sales requirement, and recapture provisions may also be debated as administrative safeguards versus burdens on manufacturers.